The round was led by Pfizer’s investment arm Pfizer Ventures, with Columbus Venture Partners and British Patient Capital joining the round along with prior investors Advent Life Sciences and Epidarex Capita.
The proceeds will be used to develop Curve’s Microcycle drug discovery platform, which the company says enables the direct discovery of biologically active molecules against targets that have been difficult to address using conventional drug discovery methods.
